Enhanced Therapeutic Microvesicles from Probiotic Bacteria
Legal Citation
Summary of the Inventive Concept
This inventive concept enhances the therapeutic efficacy, production, and delivery of microvesicles derived from probiotic bacteria, addressing limitations of existing methods and compositions.
Background and Problem Solved
The original patent disclosed therapeutic microvesicles of probiotic bacteria, but had limitations in terms of production efficiency, targeted delivery, and stability. This new inventive concept solves these problems by introducing novel methods for enhancing therapeutic efficacy, large-scale production, and personalized delivery.
Detailed Description of the Inventive Concept
The inventive concept comprises five key aspects: (1) encapsulating microvesicles in liposomes or nanoparticles for targeted delivery; (2) a system for large-scale production of microvesicles in a controlled bioreactor environment; (3) a composition of microvesicles derived from multiple probiotic bacterial strains with improved stability and shelf life; (4) a method for personalizing the therapeutic effect of microvesicles based on an individual's microbiome profile; and (5) a microvesicle-based vaccine with enhanced immune response. These aspects work together to provide a more efficient, effective, and personalized approach to therapeutic microvesicle delivery.
Novelty and Inventive Step
The new claims introduce novel and non-obvious solutions to the limitations of the original patent, including targeted delivery, large-scale production, and personalized therapy. The combination of these aspects provides a unique and inventive approach to therapeutic microvesicle technology.
Alternative Embodiments and Variations
Alternative embodiments may include different types of nanoparticles or liposomes for delivery, varying bioreactor conditions for production, or additional probiotic bacterial strains for composition. Variations may also include different administration routes or dosing regimens for personalized therapy.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the fields of pharmaceuticals, biotechnology, and healthcare. The targeted delivery and personalized therapy aspects may be particularly valuable in treating specific diseases or conditions, such as inflammatory bowel disease or cancer. The large-scale production system may also be attractive to companies seeking to commercialize therapeutic microvesicle products.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Microbiology, Biotechnology, Probiotic Bacterial Engineering, with expertise in microvesicle production, bacterial strain manipulation, and therapeutic delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degree in microbiology or biotechnology, familiar with probiotic bacterial strain characterization, microvesicle extraction techniques, and therapeutic delivery strategies
Obviousness Rationale
A PHOSITA would recognize that the proposed variations represent logical extensions of the source patent's core teachings about probiotic bacterial microvesicles, utilizing standard bioengineering techniques to enhance delivery, production, and therapeutic targeting. The modifications represent predictable improvements using known methodological approaches in bacterial therapeutic technologies. The proposed innovations emerge from standard problem-solving strategies in microbial therapeutic development.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,582 |
|---|---|
| Title | Therapeutic microvesicles of probiotic bacteria |
| Assignee(s) | BioGaia AB |